Corpus overview


Overview

MeSH Disease

Human Phenotype

Transmission

Seroprevalence

There are no seroprevalence terms in the subcorpus

    displaying 1 - 3 records in total 3
    records per page




    COVID-19 and Epilepsy MESHD

    Authors: Amira Sidig; Radi Tofaha Alhusseini; Khabab Abbasher; Mohamed Elsayed; Hussien Abbasher; Mohammed Abbasher; Sufian Khalid M. N; Khalid Hajnoor; Mohammed Malekaldar; Abbasher Hussien; Omer Eladil A. Hamid; Mutaz F. Digna

    doi:10.21203/rs.3.rs-49340/v1 Date: 2020-07-26 Source: ResearchSquare

    Introduction: COVID-19 caused by SARS-CoV-2 acquired via respiratory droplets. It can present with many systemic disorders MESHD, includingA 45-year-old Sudanese male TRANS known to have well-controlled generalized tonic-clonic epilepsy MESHD, He presented to the Accident and Emergency (A&E) department complaining of refractory status epilepticus HP status epilepticus MESHD. Despite immediate initial stabilization, the seizure HP seizure MESHD attacks were still refractory to intravenous loading doses of antiepileptic drugs AEDs. Hence the patient was intubated and mechanically ventilated. Brain MRI and EEG were normal. The chest X-ray was normal. The screening of COVID-19 was positive. Epilepsy MESHD is one of the most common neurological disorders MESHD. Since the beginning of the Coronavirus outbreak in December 2019, no available research data is suggesting that the patients with epilepsy MESHD are at more risk than others. As no available data relating epilepsy MESHD to severe COVID-19 infection (6). Moreover, no data studied COVID-19 and the sudden unexpected death MESHD among epileptic MESHD patients (SUDEP).Conclusion: This case might report the effect of SARS-CoV-2 on provoking the refractory seizures HP seizures MESHD in a previously well-controlled patient with epilepsy MESHD. More researches are needed to explain the relation between COVID and seizure HP seizure MESHD threshold.

    Neurological manifestations associated with COVID-19: a nationwide registry

    Authors: Elodie Meppiel; Nathan Peiffer-Smadja; Alexandra Maury; Imen Bekri; Cecile Delorme; Virginie Desestret; Lucas Gorza; Geoffroy Hautecloque-Raysz; Sophie Landre; Annie Lannuzel; Solene Moulin; Peggy Perrin; Paul Petitgas; Francois Sellal; Adrien Wang; Pierre Tattevin; Thomas de Broucker; - contributors to the NeuroCOVID registry

    doi:10.1101/2020.07.15.20154260 Date: 2020-07-16 Source: medRxiv

    Background: The clinical description of the neurological manifestations in COVID-19 patients is still underway. This study aims to provide an overview of the spectrum, characteristics and outcomes of neurological manifestations associated with SARS-CoV-2 infection MESHD. Methods: We conducted a nationwide, multicentric, retrospective study during the French COVID-19 epidemic in March-April 2020. All COVID-19 patients with de novo neurological manifestations were eligible. Results: We included 222 COVID-19 patients with neurological manifestations from 46 centers throughout the country. Median age TRANS was 65 years (IQR 53-72), and 136 patients (61.3%) were male TRANS. COVID-19 was severe or critical in almost half of the patients (102, 45.2%). The most common neurological diseases MESHD were COVID-19 associated encephalopathy HP encephalopathy MESHD (67/222, 30.2%), acute ischemic cerebrovascular syndrome MESHD (57/222, 25.7%), encephalitis HP encephalitis MESHD (21/222, 9.5%), and Guillain-Barre Syndrome MESHD (15/222, 6.8%). Neurological manifestations appeared after first COVID-19 symptoms with a median (IQR) delay of 6 (3-8) days in COVID-19 associated encephalopathy HP encephalopathy MESHD, 7 (5-10) days in encephalitis HP encephalitis MESHD, 12 (7-18) days in acute ischemic cerebrovascular syndrome MESHD and 18 (15-28) days in Guillain-Barre Syndrome MESHD. Brain imaging was performed in 192 patients (86.5%), including 157 MRI (70.7%). Brain MRI of encephalitis HP encephalitis MESHD patients showed heterogeneous acute non vascular lesion in 14/21 patients (66.7%) with associated small ischemic lesion or microhemorrhages MESHD in 4 patients. Among patients with acute ischemic cerebrovascular syndrome MESHD, 13/57 (22.8%) had multi territory ischemic strokes HP ischemic strokes MESHD, with large vessel thrombosis MESHD in 16/57 (28.1%). Cerebrospinal fluid was analyzed in 97 patients (43.7%), with pleocytosis MESHD in 18 patients (18.6%). A SARS-CoV-2 PCR was performed in 75 patients and was positive only in 2 encephalitis HP encephalitis MESHD patients. Among patients with encephalitis HP encephalitis MESHD, ten out of 21 (47.6%) fully recovered, 3 of whom received corticosteroids (CS). Less common neurological manifestations included isolated seizure HP seizure MESHD (8/222, 3.6%), critical illness neuropathy MESHD (8/222, 3.6%), transient alteration of consciousness (5/222, 2.3%), intracranial hemorrhage HP intracranial hemorrhage MESHD (5/222, 2.3%), acute benign lymphocytic meningitis MESHD meningitis HP (3/222, 1.4%), cranial neuropathy MESHD (3/222, 1.4%), single acute demyelinating lesion MESHD (2/222, 0.9%), Tapia syndrome MESHD (2/222, 0.9%), cerebral venous thrombosis HP cerebral venous thrombosis MESHD (1/222, 0.5%), sudden paraparesis MESHD paraparesis HP (1/222, 0.5%), generalized myoclonus HP myoclonus MESHD and cerebellar ataxia MESHD ataxia HP (1/222, 0.5%), bilateral fibular palsy (1/222, 0.5%) and isolated neurological symptoms ( headache HP headache MESHD, anosmia HP anosmia MESHD, dizziness MESHD, sensitive or auditive symptoms MESHD, hiccups MESHD, 15/222, 6.8%). The median (IQR) follow-up of the 222 patients was 24 (17-34) days with a high short-term mortality rate (28/222, 12.6%). Conclusion: Neurological manifestations associated with COVID-19 mainly included CAE, AICS, encephalitis HP encephalitis MESHD and GBS MESHD. Clinical spectrum and outcomes were broad and heterogeneous, suggesting different underlying pathogenic processes.

    Continuous Electroencephalography (cEEG) Characteristics and Acute Symptomatic Seizures HP Seizures MESHD in COVID-19 Patients

    Authors: Shreya Louis; Andrew Dhawan; Christopher Newey; Dileep Nair; Lara Jehi; Stephen Hantus; Vineet Punia

    doi:10.1101/2020.05.26.20114033 Date: 2020-05-28 Source: medRxiv

    Background: Neurological manifestations of COVID-19 have only recently been described, with a paucity of literature reporting the potential relationship between COVID-19 and acute symptomatic seizures HP seizures MESHD. Two prior studies found no clinical or electrographic seizures HP seizures MESHD in their cohorts of COVID-19 patients with altered mental status (AMS) and clinical seizure HP seizure MESHD-like events ( SLEs MESHD). Methods: In this retrospective cohort study, 22 critically-ill COVID-19 patients above the age TRANS of 18 years who underwent EEG (electroencephalography) monitoring between April 20th, 2020 and May 20th, 2020 were studied. 19 patients underwent continuous EEG (cEEG) for at least 24 hours, and 3 patients underwent routine EEGs (<1 hour). Demographics including age TRANS, gender TRANS, comorbid medical, and neurological conditions were collected. Clinical variables included EEG findings, anti- seizure HP seizure MESHD medications, discharge disposition, and survival. Findings: 17 patients underwent EEG monitoring for unexplained altered mental status changes and 5 patients underwent monitoring for a seizure HP seizure MESHD-like event. 5 patients had epileptiform abnormalities MESHD abnormalities on EEG HP (4 patients on cEEG, 1 on routine EEG); and only 2 of 5 epileptic MESHD EEG patients had a prior history of epilepsy MESHD. 2 patients in our cohort had electrographic seizures in the absence HP seizures in the absence MESHD of prior epilepsy MESHD history. No patients with epileptiform abnormalities MESHD or electrographic seizures HP seizures MESHD had acutely abnormal neuroimaging on CT or MRI. Interpretation: Encephalopathic COVID-19 positive patients had a range of EEG abnormalities HP, and a higher proportion of patients in this series had electrographic seizures HP seizures MESHD than previous literature suggests. This may be influenced by the duration of monitoring with cEEG and the use of a 21 channel electrode system. cEEG findings may help to guide antiseizure medical therapy, as well as the workup of altered mental status in the setting of unremarkable neuroimaging. Funding: No funding was used for this study.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from Preprints.org and is updated on a daily basis (7am CET/CEST).
The web page can also be accessed via API.

Sources


Annotations

All
None
MeSH Disease
Human Phenotype
Transmission
Seroprevalence


Export subcorpus as...

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.